EMA Withdrawn: Trobalt (retigabine) — Glaxo Group Limited

View source ↗

Summary

The EMA has withdrawn Trobalt (retigabine) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Trobalt (ezogabine)

Snippet

Status: Withdrawn. Therapeutic area: Epilepsy. MAH: Glaxo Group Limited. Decision date: 19/07/2018